Cytokinetics Stock News

Cytokinetics (CYTK) said a phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy ((HCM)) is open to enrollment.HCM is a disease in which the

Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional Class Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capa

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) and the American Heart Association (AHA) Bay Area announced a 3-year collaboration to accelerate education and awareness of heart disease.CYTK will provide funding…

SOUTH SAN FRANCISCO, Calif. and OAKLAND, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three

No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -33.33% and 78.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Cytokinetics Inc (CYTK) shares closed this week 22.5% higher than it did at the end of last week. The stock is currently down 13.7% year-to-date, up 69.8% over the past 12 months, and up 249.5% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $40.91 and as low as $32.08 this week.Trading volume this week was 29.2% higher than the 10-day average and 46.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -20.5% The company's stock price performance over the past 12 months beats the peer average by -223.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2022 at

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2022 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2022 at 4

Cytokinetics (CYTK) said on Friday that the FDA accepted the companys New Drug Application ((NDA)) for omecamtiv mecarbil under its standard review, giving the marketing application

PDUFA Target Action Date Set for November 30, 2022

Cytokinetics (CYTK) granted 15 new employees stock options to buy a total of 200.7K common shares as a material inducement to their employment